Pirinixic acids: Flexible fatty acid mimetics with various biological activities

Future Medicinal Chemistry

Volumn 7, Issue 12, 2015, Pages 1597-1616

  Merk, Daniel ^a   Zettl, Martina ^a   Steinhilber, Dieter ^a   Werz, Oliver ^b   Schubert Zsilavecz, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BENZENE DERIVATIVE; CELL NUCLEUS RECEPTOR; FATTY ACID; GAMMA SECRETASE; PIRINIXIC ACID; PYRIMIDINE; ANTILIPEMIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PYRIMIDINE DERIVATIVE;

BIOLOGICAL ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; PROCEDURES;

ANIMALS; DRUG DISCOVERY; HUMANS; HYPOLIPIDEMIC AGENTS; MODELS, MOLECULAR; PPAR ALPHA; PPAR GAMMA; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84940940548     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.87     Document Type: Review

References (70)

1. Santilli A, Scotese A, Tomarelli R. A potent antihypercholesterolemic agent: [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14643). Experientia 30(10), 1110-1111 (1974).
2. Tomarelli R, Bauman L, Savini S. Effect of Wy-14,643 on cholesterol metabolism in normal and hypercholesterolemic rats. Atherosclerosis 30(4), 301-311 (1978).
3. Göttlicher M, Widmark E, Li Q, Gustafsson J. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc. Natl Acad. Sci. USA 89(10), 4653-4657 (1992).
4. Rau O, Syha Y, Zettl H, Kock M, Bock A, Schubert-Zsilavecz M. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma. Arch. Pharm. (Weinheim) 341(3), 191-195 (2008).
5. Klemin S, Calvo R, Bond S et al. WY 14,643 inhibits human aldose reductase activity. J. Enzyme Inhib. Med. Chem. 21(5), 569-573 (2008).
6. Qu C, Leung S, Vanhoutte P, Man R. Wy14643 improves vascular function in the aorta of the spontaneously hypertensive rat mainly by activating peroxisome proliferator-activated receptors alpha. Eur. J. Pharmacol. 696(1-3), 101-110 (2012).
7. Barlaka E, Ledvényiová V, Galatou E et al. Delayed cardioprotective effects of WY-14643 are associated with inhibition of MMP-2 and modulation of Bcl-2 family proteins through PPAR- activation in rat hearts subjected to global ischaemia-reperfusion. Can. J. Physiol. Pharmacol. 91(8), 608-616 (2013).
8. Yoo S, Abdelmegeed M, Song B-J. Activation of PPAR by Wy-14643 ameliorates systemic lipopolysaccharide-induced acute lung injury. Biochem. Biophys. Res. Commun. 436(3), 366-371 (2013).
9. Zahradka P. Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist Wy14,643. Cardiovasc. Drug Rev. 25(2), 99-122 (2007).
10. Nemeková M, arnická S, Ferko M, Muráriková M, Ledvényiová V, Ravingerová T. Treatment of rats with hypolipidemic compound pirinixic acid protects their hearts against ischemic injury: are mitochondrial K(ATP) channels and reactive oxygen species involved Physiol. Res. 62(5), 577-584 (2013).
11. Teoh N, Williams J, Hartley J, Yu J, McCuskey R, Farrell G. Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury. Hepatology. 51(3), 996-1006 (2010).
12. Xu S, Li Y, Hu S, Chen K, Dong L. Effects of Wy14643 on hepatic ischemia reperfusion injury in rats. World J. Gastroenterol. 14(45), 6936-6942 (2008).
13. Larter C, Yeh M, Van Rooyen D, Brooling J, Ghatora K, Farrell G. Peroxisome proliferator-activated receptor agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 27(2), 341-350 (2012).
14. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39(5), 1286-1296 (2004).
15. Chou C, Haluzik M, Gregory C et al. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J. Biol. Chem. 277(27), 24484-24489 (2002).
16. Reichenbach G, Starzinski-Powitz A, Sloane B et al. PPAR agonist Wy14643 suppresses cathepsin B in human endothelial cells via transcriptional, post-transcriptional and post-translational mechanisms. Angiogenesis 16(1), 223-233 (2013).
17. Cunard R, DiCampli D, Archer D et al. WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J. Immunol. 169(12), 6806-6812 (2002).
18. Colville-Nash P, Willis D, Papworth J et al. The peroxisome proliferator-activated receptor alpha activator, Wy14,643, is anti-inflammatory in vivo. Inflammopharmacology 12(5-6), 493-504 (2005).
19. d'Atri G, Gomarasca P, Resnati G, Tronconi G, Scolastico C, Sirtori C. Novel pyrimidine and 1,3,5-triazine hypolipidemic agents. J. Med. Chem. 27(12), 1621-1629 (1984).
20. Merk D, Schubert-Zsilavecz M. Nuclear receptors as pharmaceutical targets: rise of FXR and rebirth of PPAR? Future Med. Chem. 4(5), 587-588 (2012).
21. Home P, Pocock S, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373(9681), 2125-2135 (2009).
22. Choi H, Shin W, Lee J, Kang B. Safety and efficacy of fibrate-statin combination therapy compared with fibrate monotherapy in patients with dyslipidemia: a meta-analysis. Vascul. Pharmacol. 65-66, 23-30 (2014).
23. Milionis H. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe? Expert Opin. Drug Saf. 13(3), 267-269 (2014).
24. Kota S, Meher L, Rao E, Jammula S, Modi K. Efficacy and safety of statin and fibrate combination therapy in lipid management. Diabetes Metab. Syndr. 6(3), 173-174 (2012).
25. Senekeo-Effenberger K, Chen S, Brace-Sinnokrak E et al. Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation. Drug Metab. Dispos. 35(3), 419-427 (2007).
26. Cunningham M. Toxicity studies of WY-14,643 (CAS No. 50892-23-4) administered in feed to male Sprague-Dawley rats, B6C3F1 mice, and Syrian hamsters. Toxic. Rep. Ser. (62), 1-136 (2007).
27. Suzuki T, Jin M, Dewa Y et al. Evaluation of in vivo liver genotoxic potential of Wy-14,643 and piperonyl butoxide in rats subjected to two-week repeated oral administration. Arch. Toxicol. 84(6), 493-500 (2010).
28. Trapp C, Schwarz M, Epe B. The peroxisome proliferator WY-14,643 promotes hepatocarcinogenesis caused by endogenously generated oxidative DNA base modifications in repair-deficient Csbm/m/Ogg1-/-mice. Cancer Res. 67(11), 5156-5161 (2007).
29. Morimura K, Cheung C, Ward J, Reddy J, Gonzalez FJ. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 27(5), 1074-1080 (2006).
30. Woods C, Burns A, Bradford B et al. WY-14,643 induced cell proliferation and oxidative stress in mouse liver are independent of NADPH oxidase. Toxicol. Sci. 98(2), 366-374 (2007).
31. Moennikes O, Stahl S, Bannasch P, Buchmann A, Schwarz M. WY-14,643-mediated promotion of hepatocarcinogenesis in connexin32-wild-type and connexin32-null mice. Carcinogenesis 24(9), 1561-1565 (2003).
32. Johnson T, Zhang X, Shi S, Umbenhauer D. Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. Toxicol. Appl. Pharmacol. 208(3), 210-221 (2005).
33. Giral H, Villa-Bellosta R, Catalán J, Sorribas V. Cytotoxicity of peroxisome proliferator-activated receptor alpha and gamma agonists in renal proximal tubular cell lines. Toxicol. In vitro. 21(6), 1066-1076 (2007).
34. Ozaki K, Mahler J, Haseman J, Moomaw C, Nicolette M, Nyska A. Unique renal tubule changes induced in rats and mice by the peroxisome proliferators 2,4-dichlorophenoxyacetic acid (2,4-D) and WY-14643. Toxicol. Pathol. 29(4), 440-450.
35. Zungu M, Young M, Stanley W, Essop M. Chronic treatment with the peroxisome proliferator-activated receptor alpha agonist Wy-14,643 attenuates myocardial respiratory capacity and contractile function. Mol. Cell. Biochem. 330(1-2), 55-62 (2009).
36. Zungu M, Felix R, Essop M. Wy-14,643 and fenofibrate inhibit mitochondrial respiration in isolated rat cardiac mitochondria. Mitochondrion. 6(6), 315-322 (2006).
37. Bernardes A, Souza P, Muniz J et al. Molecular mechanism of peroxisome proliferator-activated receptor activation by WY14643: a new mode of ligand recognition and receptor stabilization. J. Mol. Biol. 425(16), 2878-2893 (2013).
38. Liberato M, Nascimento A, Ayers S et al. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) activators and pan-PPAR partial agonists. PLoS ONE 7(5), e36297 (2012).
39. Amato A, Rajagopalan S, Lin J et al. GQ-16, a novel peroxisome proliferator-activated receptor (PPAR) ligand, promotes insulin sensitization without weight gain. J. Biol. Chem. 287(33), 28169-28179 (2012).
40. Ambrosio A, Dias S, Polikarpov I, Zurier R, Burstein S, Garratt R. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 282(25), 18625-18633 (2007).
41. Lamers C, Flesch D, Schubert-Zsilavecz M, Merk D. Novel prostaglandin receptor modulators: a patent review (2002-2012)-part I: non-EP receptor modulators. Expert Opin. Ther. Pat. 23(1), 47-77 (2013).
42. Meirer K, Steinhilber D, Proschak E. Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. Basic Clin. Pharmacol. Toxicol. 114(1), 83-91 (2014).
43. Agostinho P, Pliássova A, Oliveira C, Cunha R. Localization and trafficking of amyloid protein precursor and secretases: impact on Alzheimer's disease. J. Alzheimers. Dis. 45(2), 329-347 (2015).
44. Zhang X, Li Y, Xu H, Zhang Y. The -secretase complex: from structure to function. Front. Cell. Neurosci. 8, 427 (2014).
45. Jurisch-Yaksi N, Sannerud R, Annaert W. A fast growing spectrum of biological functions of -secretase in development and disease. Biochim. Biophys. Acta 1828(12), 2815-2827 (2013).
46. Mikulca J, Nguyen V, Gajdosik D et al. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. J. Clin. Pharm. Ther. 39(1), 25-37 (2014).
47. Hall A, Patel T. -Secretase modulators: current status and future directions. Prog. Med. Chem. 53, 101-145 (2014).
48. Pettersson M, Stepan A, Kauffman G, Johnson D. Novel -secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012. Expert Opin. Ther. Pat. 23(10), 1349-1366 (2013).
49. Thieme T, Steri R, Proschak E, Paulke A, Schneider G, Schubert-Zsilavecz M. Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator. Bioorg. Med. Chem. Lett. 20(8), 2469-2473 (2010).
50. Werz O, Greiner C, Koeberle A et al. Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. J. Med. Chem. 51(17), 5449-5453 (2008).
51. Popescu L, Rau O, Böttcher J, Syha Y, Schubert-Zsilavecz M. Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists. Arch. Pharm. (Weinheim). 340(7), 367-371 (2007).
52. Zettl H, Dittrich M, Steri R et al. Novel pirinixic acids as PPAR preferential dual PPAR/ agonists. QSAR Comb. Sci. 28(5), 576-586 (2009).
53. Koeberle A, Zettl H, Greiner C, Wurglics M, Schubert-Zsilavecz M, Werz O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J. Med. Chem. 51(24), 8068-8076 (2008).
54. Hieke M, Greiner C, Thieme T, Schubert-Zsilavecz M, Werz O, Zettl H. A novel class of dual mPGES-1/5-LO inhibitors based on the -naphthyl pirinixic acid scaffold. Bioorg. Med. Chem. Lett. 21(5), 1329-1333 (2011).
55. Lamers C, Dittrich M, Steri R, Proschak E, Schubert-Zsilavecz M. Molecular determinants for improved activity at PPAR: structure-activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPAR. Bioorg. Med. Chem. Lett. 24(16), 4048-4052 (2014).
56. Hanke T, Dehm F, Liening S et al. Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo. J. Med. Chem. 56(22), 9031-9044 (2013).
57. Hanke T, Lamers C, Gomez R, Schneider G, Werz O, Schubert-Zsilavecz M. Identification of pirinixic acid derivatives bearing a 2-aminothiazole moiety combines dual PPAR/ activation and dual 5-LO/mPGES-1 inhibition. Bioorg. Med. Chem. Lett. 24(16), 3757-3763 (2014).
58. Zettl H, Steri R, Lämmerhofer M, Schubert-Zsilavecz M. Discovery of a novel class of 2-mercaptohexanoic acid derivatives as highly active PPARalpha agonists. Bioorg. Med. Chem. Lett. 19(15), 4421-4426 (2009).
59. Lamers C, Schubert-Zsilavecz M, Merk D. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present). Expert Opin. Ther. Pat. 22(7), 803-841 (2012).
60. Kalinin S, Richardson J, Feinstein D. A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr. Alzheimer Res. 6(5), 431-437 (2009).
61. Benedetti E, D'Angelo B, Cristiano L et al. Involvement of peroxisome proliferator-activated receptor / (PPAR /) in BDNF signaling during aging and in Alzheimer disease: possible role of 4-hydroxynonenal (4-HNE). Cell Cycle. 13(8), 1335-1344 (2014).
62. Greiner C, Zettl H, Koeberle A et al. Identification of 2-mercaptohexanoic acids as dual inhibitors of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1. Bioorg. Med. Chem. 19(11), 3394-33401 (2011).
63. Hieke M, Ness J, Steri R et al. Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity. J. Med. Chem. 53(12), 4691-4700 (2010).
64. Hieke M, Ness J, Steri R et al. SAR studies of acidic dual -secretase/PPAR modulators. Bioorg. Med. Chem. 19(18), 5372-5382 (2011).
65. Pellowska M, Stein C, Pohland M et al. Pharmacokinetic properties of MH84, a -secretase modulator with PPAR? agonistic activity. J. Pharm. Biomed. Anal. 102, 417-424 (2015).
66. Hieke M, Greiner C, Dittrich M et al. Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid. J. Med. Chem. 54(13), 4490-4507 (2011).
67. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 405(6785), 421-424 (2000).
68. Koeberle A, Rossi A, Zettl H et al. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J. Pharmacol. Exp. Ther. 332(3), 840-848 (2010).
69. Greiner C, Hörnig C, Rossi A et al. 2-(4-(Biphenyl-4-ylamino)-6-chloropyrimidin-2-ylthio)octanoic acid (HZ52)a novel type of 5-lipoxygenase inhibitor with favourable molecular pharmacology and efficacy in vivo. Br. J. Pharmacol. 164(2b), 781-793 (2011).
70. Revermann M, Mieth A, Popescu L et al. A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine model of aortic aneurysm. Br. J. Pharmacol. 163(8), 1721-1732 (2011).